The company was founded in 2007 by a team of experts in neuroscience and nervous system modeling, and has quickly become a world leader in the field of CNS biosimulation. Rhenovia's technology allows for the creation of computational models that simulate the condition of healthy individuals or those affected by pathologies of the nervous system, predicting the effectiveness and toxicity of molecules and combinations of molecules. The company has already discovered new drug candidates for Huntington's disease and identified toxicity or side-effects of molecules under development. Rhenovia offers service offers or research and development partnerships to the pharma and biotech industry, reducing new drug development timelines while decreasing risks and associated costs.